Business Description

Overview ADC Therapeutics is a commercial-stage global pioneer in the field of antibody drug conjugates (“ADCs”), transforming treatment for patients through our focused portfolio with ZYNLONTA (loncastuximab tesirine-lpyl), a CD19-directed ADC. ZYNLONTA received accelerated approval from the U.S. Food and Drug Administration (“FDA”) and conditional approval from the European Commission, China National Medical Products Administration (“NMPA”) and Health Canada for the treatment of relapsed or refractory DLBCL after two or more lines of systemic therapy. We are pursuing expansion of ZYNLONTA internationally, and into earlier lines of diffuse large B-cell lymphoma (“DLBCL”) through our LOTIS-5 confirmatory Phase 3 clinical trial (rituximab combination) and LOTIS-7 Phase 1b clinical trial (bispecific combination) as well as into indolent lymphomas, including marginal zone lymphoma (“MZL”) and follicular lymphoma (”FL”), through investigator-initiated trials (“IITs”) at leading institutions. Headquartered in Lausanne (Biopôle), Switzerland, with operations in New Jersey, ADC Therapeutics is focused on driving innovation in ADC development with specialized capabilities from clinical development to manufacturing and commercialization. Our Product and Pipeline The following table provides an overview of our current approved product and pipeline: In addition to the current approved product and pipeline above, IND-enabling activities for ADCT-241 (the Company’s exatecan-based, prostate-specific membrane antigen (PSMA)-targeting ADC) were completed at the end of 2025. The Company continues to explore partnership opportunities. Our Strategy and Competitive Capabilities Our goal is to be a leading ADC company bringing meaningful therapies to patients in need by leveraging our decade-long experience in the ADC field, with multiple INDs, and a proven track record of success. We are focused on maximizing the ZYNLONTA opportunity. By leveraging our clinical development expertise and established commercial infrastructure, we are uniquely capable of expanding ZYNLONTA into earlier lines of DLBCL and indolent lymphomas as a single agent and in combination with other therapies. Further, our robust in-house chemistry, manufacturing and controls (“CMC”) capabilities utilize a highly experienced workforce to manage a top-tier external manufacturing network through third-party contract manufacturing organizations (“CMOs”) capable of manufacturing highly potent molecules and complex biologics. 1 Table of Contents Currently approved as a monotherapy, ZYNLONTA has a differentiated profile with rapid, deep and durable efficacy as well as manageable safety with simple and convenient administration. Based on data from our LOTIS-2 trial, ZYNLONTA provides rapid responses with the median time to response of 1.5 months. Responses were durable for patients with a complete response and the median duration of complete response had not yet been reached at the 2-year follow-up. ZYNLONTA has a manageable safety profile with no cytokine release syndrome (“CRS”) or Immune Effector Cell-Associated Neurotoxicity Syndrome (“ICANS”) and no cumulative irreversible toxicities reported in the LOTIS-2 trial. ZYNLONTA offers accessibility for patients with a simple Q3W dosing with no Risk Evaluation and Mitigation Strategies (“REMS”) or in-patient stay requirements. As a monotherapy, we believe ZYNLONTA’s profile is well-positioned for patients who do not have access to more complex therapies like CAR-T and bispecific antibodies and for patients who have progressed post CAR-T and/or bispecific antibodies. ZYNLONTA Our strategy is to maximize and expand the ZYNLONTA opportunity in several ways: • Maximize ZYNLONTA in third-line plus (“3L+”) DLBCL . We are driving utilization of ZYNLONTA in the 3L+ DLBCL setting through increased awareness of ZYNLONTA’s efficacy and manageable safety profile and its suitability for use across treatment settings. • Seek to expand ZYNLONTA into earlier lines of DLBCL and indolent lymphomas . We are studying the potential to move ZYNLONTA into earlier lines of therapy in combination with rituximab (LOTIS-5) and glofitamab (LOTIS-7) through our clinical trials and supporting IIT studies that are exploring the potential of ZYNLONTA alone or in combination with rituximab in indolent lymphomas.…